Press Releases

Today, Congressman Bill Huizenga (R-MI) released the following statement after the Trump Administration and Pfizer announced a major price reduction agreement that will lower costs for Americans, including Medicaid recipients, in Southwest Michigan and across America. Pfizer also announced it has agreed to participate in the new direct-to-consumer TrumpRx.gov. This platform will allow Americans to purchase medicines, including primary care treatments and some specialty brands from Pfizer, that will be offered with savings up to 85% and an average of 50%.

“This announcement from Pfizer will have a significant cost-savings impact on Medicaid recipients, seniors, and families across the United States,” said Congressman Bill Huizenga. “I applaud Pfizer for their leadership and working with the Trump Administration to lower prescription drug prices and make life-saving medications more affordable for Americans.”

“I have long called for the strengthening of our domestic supply chains and reshoring of critical pharmaceutical and base chemical production in America,” continued Huizenga. “Pfizer’s decision to invest $70 billion in research and development, as well as domestic manufacturing here in the United States, is critical to achieving this goal. It is my hope that Pfizer will continue its long-standing partnership with Southwest Michigan and make further investments in Kalamazoo County.”